Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Investors from the cold call sales pitches cannot be happy the way this is trending.
Pennexx is getting active on Twitter.
2 posts today....both about the app.
Check out @PENNEXX
Short selling has nothing to do here.
You cannot short this any lower than it is now. Nobody is holding a short position on RNVA.
You do NOT always post facts.
You have repeatedly posted the O/S as being 10 Billion from a very old podcast.
Magniant still lists Sofpulse as a product they market. They were also targeting the VA.
Alan,
What happened to this partnership?
https://www.magniant.com/endonovo-release
Nobody is shorting this stock. It's at the bottom already. The margin requirement would be too big to hang on to this stock for any length of time. It has already bottomed out for a while.
Joe must be selling shares for his retirement cruise...LOL
Most likely due to this statement in the mining docs.... "The proposed exploration under the EPL 8724 is the first of its kind in the area. The
exploration process is likely to be slow...."
Anyone with an iPhone going to try and be a Beta tester?
I hope the recent tweet about an "exciting announcement" was not for this PR.
This PR was a rehash of all past PRs just as you said.
They should have mentioned status of the Ocean Tomo analysis which was "expected to be completed in Q1" as quoted by Alan.
There should have been an update on this.
Just another example of a delay or a cancelled event that is not addressed and swept under the rug.
I don't believe he would intentionally laugh at someone losing money. But when people are pumping unrealistic or untrue numbers as facts and then laughing at someone that counters with facts that prove otherwise....then it just turns into a tit for tat situation.
What happened with the "signing of a definitive purchase agreement for Endonovo to acquire all of Western Star’s assets and business operations."???
This was PR'd 11 months ago.
A good "update" would inform shareholders of pending acquisitions that seemed to be imminent and talked about millions in revenue.
We will have to assume that deal fell through and is no longer happening. Collier never addresses shareholders when something bad happens or does not happen at all. It appears Western Star has been swept under the rug.
Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update
Los Angeles, CA, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics Inc. (OTCQB: ENDV) -- commercial developer of medical technology-- is proud to announce a series of advancements in the first half of 2023.
The Company has made significant strides in multiple areas of sales, marketing, branding, management and financing. These milestones give management confidence for sustained growth and substantial revenues. The Company is focusing on its FDA Cleared Pulsed Electro Magnetic Field (PEMF) technologies and the telehealth industries.
Hiring President to Guide SofPulse® Global Growth
Endonovo's hiring of Ira Weisberg as President and Chief Commercial Officer in December 2022 has proven to be successful. The strategic hiring of Weisberg to lead sales, marketing and brand initiatives is set to drive Endonovo's expansion and distribution efforts.
Weisberg’s distinguished career spans over four decades in healthcare and pharmaceutical management, business development, finance, sales and marketing. He brings a wealth of expertise to the table and has helped to propel Endonovo's non-opioid pain management initiatives and the expansion of PEMF therapies both domestically and internationally.
Market Penetration and Brand Expansion
Endonovo is successfully expanding its reach to new regions and increasing brand awareness domestically and internationally. The Company's innovative approach to pain relief and non-opioid alternatives has garnered widespread attention in expanding medical markets. The Company has been successful in expanding contracts to grow market and brand initiatives to better service in-patient, out-patient, wellness and direct-to-consumer markets.
“Management believes that the actions taken during the first two quarters of 2023 have strategically positioned our products to make substantial revenues in the growing $400 billion pain/telehealth markets,” Weisberg stated.
Expanded Distribution for Veterans and Military Personnel
Endonovo continues to be dedicated to supporting veterans and active-duty military personnel who have served our nation with honor and dedication. In the first quarter of 2023, we solidified a strategic partnership with Academy Medical, a leading distribution company, serving Veterans and Dept of Defense patients. The Veteran Health Administration (VA) is its largest customer.
The agreement can help to play a pivotal role in delivering essential PEMF- therapies and medical products to government facilities. To prepare for scalable growth, Endonovo is in the process of building dedicated sales and marketing initiatives to support the growth of its expanded distribution contracts.
"We are thrilled with the progress we have made in the last six months, and we remain steadfast in our mission to transform pain and inflammation relief and develop telehealth solutions. With our pioneering PEMF technology and strategic initiatives, we are poised for continued growth and success,” Weisberg said.
Scientific Research and Advancements in Patent Technology
The Company looks to continue its research and development efforts to develop through its PEMF patents to address Central Nervous System (CNS) disorders and reduce inflammation symptoms related to Traumatic Brain Injury (TBI), Post-Concussion Syndrome (PCS), Multiple Sclerosis (MS), dementia, Alzheimer’s disease and ischemic stroke.
Present and past studies utilizing SofPulse® at highly regarded institutions, including Stanford University and Columbia University, further demonstrate our commitment to evidence-driven medical solutions.
Our ongoing scientific research has positioned us to seize new revenue opportunities in the rapidly expanding CNS and TBI global treatment markets. According to Grand View Research, the global market for CNS therapeutics was valued at $116.2 billion in 2020, projected to grow at a remarkable Compound Annual Growth Rate (CAGR) of 7.4% from 2021 to 2028, reaching $214.8 billion in 2028. The market for TBI treatment alone is estimated to surge from $3.1 billion in 2021 to $4.5 billion in 2026, as reported by Global Market Estimates.
Advancement of TBI Research
Over the past six months, SofPulse® PEMF Therapy has garnered overwhelmingly positive responses from renowned clinical researchers and top global cognitive institutes to evaluate the incredible potential in alleviating TBI symptoms. Proposed studies aim to target acute head injuries, including concussions and Post-Concussion Syndrome (PCS), with expected results to alleviate headaches, dizziness and cognitive impairment.
Endonovo influencer David Irving, a former NFL Dallas Cowboy and Las Vegas Raider Defensive lineman, brings personal experience to the forefront. Having faced over 20 concussions by the age of 26, David joins us to recruit fellow athletes experiencing ongoing TBI symptoms for our transformative studies.
Empowering Healthcare Solutions Worldwide
Endonovo's international expansion strategy is accelerating. In partnership with an international distribution company, EverMed Inc, we eagerly await Taiwan FDA approval to bring the groundbreaking SofPulse® medical device to the country. Our distribution efforts in Mexico and Costa Rica have already resulted in substantial orders, generating hundreds of thousands of dollars in revenue.
Moving forward, the Company’s sights are set on expansion into key markets such as: Australia, South America, Europe, South Korea, Thailand and Singapore. Initial response and contract negotiations have exhibited that the global medical markets are taking notice of our innovative pain relief solutions and non-opioid alternatives. Endonovo looks to expand international distribution efforts and believes they will be driving our mission to revolutionize healthcare accessibility worldwide. Together with our international partners, we are poised to shape a healthier, pain-free future for people across the globe.
Telehealth Offers Healthcare Access Anywhere, Anytime
The future of healthcare is taking a bold leap forward with Endonovo's telehealth initiative. Over the first half of 2023, we have achieved significant milestones in designing and developing a comprehensive telemedicine platform set to redefine how medical services and cutting-edge devices reach the masses.
Through our telehealth platform, veterans, active-duty personnel, and civilians alike will have seamless access to medical guidance and advanced pain management solutions from the comfort of their homes or “on the go”. To realize this ambitious endeavor, Endonovo has partnered with a leading telehealth developer known for pioneering transformative solutions in the Telemedicine Industry.
Weisberg concluded his review of the first half of 2023: “SofPulse® is the only FDA-cleared, non-narcotic, holistic pain-relieving product able to get pain sufferers back to their lives faster with an improved quality of life. Our PEMF therapies bolster our belief that better access to our therapies will lead us to live better lives.”
Wait until the next Q comes out and you see the increased outstanding share count.
Good luck to the pumpers.....will have to update their statistics for the pumping.
Will be hard to cheerlead a FAT outstanding share count.....LOL. LOL
His point is that this release of information was only posted on OTC Markets and was not released through official news channels.
An official PR would get new and more eyes on it.
A simple upload to OTC Markets will only be seen by current investors that are continuously following it already.
PENNEXX Begins Beta Testing of its Your Social Offers Smartphone App in Apple TestFlight and on AndroidPress Release | 08/07/2023
PHILADELPHIA, PA / ACCESSWIRE / August 7, 2023 / Pennexx Foods (OTC PINK:PNNX) Pennexx has begun beta testing of its smartphone savings app in Apple TestFlight and on Android. Apple TestFlight allows beta testers to download the YourSocialOffers.com (YSO) smartphone app onto their iOS phones and updates as new versions become available. The company's app has been approved by Apple for external testing. this means that the company is now able to invite individuals outside of the company to test the app. The company has shared the app with a number of testers including partners and potential buyers for zip code areas.
Vincent Risalvato, CEO of Pennexx said, "It is very exciting to see the company so close to the next step of the YSO app on the Apple and Google app stores. This app greatly enhances the interaction between consumers and merchants bringing new features and an exciting opportunity to the company."
The YSO App is using GPS technology to customize the consumer experience to show offers and deals that are close to their location and certain aspects of the app can be tailored to the location.
The consumer can also input a search to find offers and deals for an area that they are traveling to making the app a good tool for finding potential travel deals.
The new YSO App also has new gamification features to make consumers continue to interact with the app after their initial use to save money. This is a very successful strategy employed by other apps such as Temu™ to keep consumers engaged. What this means for merchants is that their products and offers have more exposure to consumers.
What it means for licensed resellers of YSO is that they have more features to sell the merchants and a more successful experience.
For consumers, it means they can win some great prizes for merely interacting with the app.
Since the app can recognize the location of the user, it can popup when the consumer gets near a place that has an active YSO offer. This will be another way the YSO licensee will be able to show the value of the YSO system because it will drive consumers into stores when they see offers are available.
The company will be releasing screenshots and additional details about the app on twitter @Pennexx.
That podcast seems to be a paid promotional campaign from RNVA...lol
Stock Day Media may receive direct compensation of $500 to $10,000 for content and or advertisements.
That is a very outdated interview and there are 30 BILLION+ shares outstanding.
New board members bring in new vision.
Conflict of ideas.
Joe says.... I'm too old for this.
Retires and enjoys the sunsets on the beach.
My wild guess of course.
I would like to hear your reasoning with how this stock will achieve a price of .05-.10 with a float that will be greater than 30 BILLION (after the next Q is released).
What are the numbers to support that projection?
There you go....you see the 30 Billion?
Why do you keep posting the Logan quote of 10 Billion when you know that 10B is outdated????
You say you like to post "Facts" but bend the truth by reposting outdated numbers.
Tweet from ENDV
Please stay tuned. Very exciting times at $ENDV we have a pending announcement as well as several updates coming soon!
Wow....that is sneaky.
I know the bulls will say an acquisition is coming and they need restricted shares for the purpose of the acquisition.
Do they still have friends and family waiting for their easy payday?
Ok... I'll bite.
Please explain your theory of how market makers are holding this down for someone to accumulate.
Who is dumping the shares that are being accumulated?
Where are the shares that are being sold coming from?
My vote is for #2.
With Crash and Berns on complete radio silence, perhaps that was part of the deal to get shares for sale.
If he did get shares....better have a PR soon or this will go sub penny with little bid support.
Must be delivering by horse and carriage. Hehe.
How does BIEL get an Institutional Investor being a non SEC filing company with UNaudited financials?
There has been a lot of selling this past week. The past few trading days have had more sells than buys by a large margin.
Micro stock?
How is an O/S of 30 BILLION + a micro stock?
LOL
These past few trading days with high volume have been mostly sells on the Bid.
Seems conversions are not completely finished yet.
A reverse split will be required for uplisting purpose. There is no avoiding that.
If the convertible notes are gone..a reverse split will not be a bad thing.
The Direct To Consumer should help increase sales. The prescription requirement makes it harder for people to acquire and try it.
Do you know what changes have to be made to remove the prescription requirement and allow it to be freely available?
Why was it originally setup that way by Ivivi?
I doubt it. There is no indication of that. He would be doing the cleanup process.
He is not associated with this one.
It was a scam when operated by a group of Chinese people in the past.
It has a new custodian company working to bring it current and sell the shell to a new private company looking to go public.
Only if you live in Canada and can buy expert market stocks.
This shell is being cleaned up with financials being worked on to be brought Pink Current once again.
Stay tuned.
Where are you getting the float number from?
There is no way this has only a 8B float.
Yes...you are correct....there are so many different Preferred share classes. It is mind boggling.
Thanks for the correction.
Your posts are refreshing on this board as they are to the point and without baseless pumping or bashing.
The net income profit is still far away from paying off the millions upon millions of debt it has to pay off.
Selling of shares is going slowly.
It takes too many shares to have a value substantial enough to make a dent with the convertible debt.
To move the the needle in stock price it will take unprecedented volume to get out of trip 1s.
You are correct...R/S is not happening....yet.
It will have to happen eventually.
Why do you think the A/S is at 250 Billion??
Do you think the stock can ever get out of trips with a 250 Billion float?
Have you calculated what the market cap would be with a 250 billion shares count and price projections people are throwing out there?
There is no need for a R/S now as there is still room to dilute into the A/S.